{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:29:51Z","timestamp":1795195791205,"version":"4.10.3"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Data on antiviral treatment for infants with chronic hepatitis B (CHB) are limited. This study is aimed to investigate whether and how antiviral treatment can achieve a functional cure in infants with CHB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This real-world study enrolled 21 infants (9 boys and 12 girls) with active hepatitis B e antigen (HBeAg)-positive CHB from the Fifth Medical Center of Chinese PLA General Hospital, who were perinatally infected with hepatitis B virus (HBV) by mother-to-child transmission. The median baseline age was 9 months. Twenty-one cases initially received Lamivudine (LAM) monotherapy, and interferon-\u03b1 (IFN-\u03b1) treatment was added when they were more than 12 months old. The virological responses, functional cure, and treatment safety were analyzed for 36 months (treatment plus follow-up visit duration).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      All 21 infants with CHB (baseline median HBV DNA was 7.75 log\n                      <jats:sub>10<\/jats:sub>\n                      IU\/mL) had full viral suppression on antiviral treatment, and the median time taken for undetectable HBV DNA was 6 months (range: 1\u201319 months). Correspondingly, the median time taken for HBeAg seroconversion was 7 months (range: 3\u201318 months) for 20 infants, and one case did not obtain HBeAg seroconversion; 19 of the 21 infants achieved a functional cure through a median time of 9 months (range: 4\u201327 months) since baseline. Two infants did not achieve a functional cure at the 36-month endpoint, but they achieved undetectable HBV DNA, and one of them had HBeAg seroconversion. Flu-like symptoms associated with IFN-\u03b1 treatment were the common side effects; however, no serious adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our findings indicate that under 1-year-old infants with active CHB can achieve a significantly high probability of a functional cure when they receive a definite duration of antiviral treatment using LAM add-on IFN-\u03b1 therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003847","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:00:14Z","timestamp":1767589214000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["High rate of functional cure in infants with chronic hepatitis B following a definite duration of antiviral treatment"],"prefix":"10.1097","author":[{"given":"Jing","family":"Li","sequence":"first","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China"},{"name":"Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084\u200c, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Fan","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China"},{"name":"Peking University 302 Clinical Medical School, Beijing 100039, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Dong","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junliang","family":"Fu","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglei","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Guo","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China"},{"name":"Peking University 302 Clinical Medical School, Beijing 100039, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"R1-20260105","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S2468-1253(19)30042-1","article-title":"Hepatitis B virus infection in children and adolescents","volume":"4","author":"Indolfi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R2-20260105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41591-023-02782-x","article-title":"Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China","volume":"30","author":"Yin","year":"2024","journal-title":"Nat Med"},{"key":"R3-20260105","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/aogs.14448","article-title":"Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis","volume":"101","author":"Yao","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R4-20260105","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/jgh.12550","article-title":"Management of chronic hepatitis B in children: An unresolved issue","volume":"29","author":"Della Corte","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"R5-20260105","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/hep4.1875","article-title":"Aiming for functional cure with established and novel therapies for chronic hepatitis B","volume":"6","author":"Choi","year":"2022","journal-title":"Hepatol Commun"},{"key":"R6-20260105","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/hep.30312","article-title":"Combination of Entecavir\/peginterferon alfa-2a in children with hepatitis B e antigen-positive immune tolerant chronic hepatitis B virus infection","volume":"69","author":"Rosenthal","year":"2019","journal-title":"Hepatology"},{"key":"R7-20260105","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12664-018-0878-1","article-title":"Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B: First study in children","volume":"37","author":"Lal","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"R8-20260105","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12072-023-10631-9","article-title":"Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B","volume":"18","author":"Zhang","year":"2024","journal-title":"Hepatol Int"},{"key":"R9-20260105","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/apt.17667","article-title":"Age at treatment initiation predicts response in children with chronic hepatitis B","volume":"58","author":"Wu","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"R10-20260105","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1097\/CM9.0000000000003383","article-title":"Chinese guidelines for the diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome (2024 edition)","volume":"137","year":"2024","journal-title":"Chin Med J"},{"key":"R11-20260105","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2019.06.009","article-title":"Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B","volume":"71","author":"Zhu","year":"2019","journal-title":"J Hepatol"},{"key":"R12-20260105","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.12998\/wjcc.v9.i14.3442","article-title":"Successful treatment of infantile hepatitis B with lamivudine: A case report","volume":"9","author":"Zhang","year":"2021","journal-title":"World J Clin Cases"},{"key":"R13-20260105","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1177\/0091270011426563","article-title":"Developmental pharmacokinetic changes of Lamivudine in infants and children","volume":"52","author":"Tremoulet","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"R14-20260105","first-page":"145","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"3","author":"You","year":"2023","journal-title":"Infect Dis Immun"},{"key":"R15-20260105","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018\u202fhepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"R16-20260105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/ID9.0000000000000122","article-title":"Expert consensus on the prevention and treatment of chronic hepatitis B in children","volume":"4","year":"2024","journal-title":"Infect Dis Immun"},{"key":"R17-20260105","first-page":"1011","article-title":"Functional cure of chronic hepatitis B with antiviral treatment in children having high-level viremia and normal or mildly elevated serum aminotransferase","volume":"11","author":"Li","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"R18-20260105","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.antiviral.2012.08.008","article-title":"Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B","volume":"96","author":"Zhao","year":"2012","journal-title":"Antiviral Res"},{"key":"R19-20260105","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.3748\/wjg.15.4311","article-title":"Baseline predictors of virological response for chronic hepatitis B patients","volume":"15","author":"Wu","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R20-20260105","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/341508","article-title":"Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins","volume":"186","author":"Marx","year":"2002","journal-title":"J Infect Dis"},{"key":"R22-20260105","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"R23-20260105","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cgh.2024.07.036","article-title":"Predictors of functional cure of chronic hepatitis B virus infection: A long-term follow-up study","volume":"23","author":"Wu","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R24-20260105","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12072-023-10597-8","article-title":"Why is the functional cure rate of young children with chronic hepatitis B receiving antiviral therapy considerably high?","volume":"18","author":"Wang","year":"2024","journal-title":"Hepatol Int"},{"key":"R25-20260105","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","article-title":"Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B","volume":"143","author":"Kennedy","year":"2012","journal-title":"Gastroenterology"},{"key":"R26-20260105","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1136\/gutjnl-2021-326258","article-title":"HBV antigens quantity: Duration and effect on functional cure","volume":"71","author":"Bertoletti","year":"2022","journal-title":"Gut"},{"key":"R27-20260105","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jhep.2024.06.037","article-title":"Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome","volume":"81","author":"Zoulim","year":"2024","journal-title":"J Hepatol"},{"key":"R28-20260105","first-page":"130","article-title":"Clinical manifestations and pathological changes of hepatitis B and C in children","volume":"19","author":"Zhang","year":"2006","journal-title":"ChuanRan Bing XinXi"},{"key":"R29-20260105","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1186\/s12879-024-09723-0","article-title":"Functional cure induced by tenofovir alafenamide plus peginterferon-alpha-2b in young children with chronic hepatitis B: A case series study","volume":"24","author":"Zeng","year":"2024","journal-title":"BMC Infect Dis"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:33:42Z","timestamp":1786037622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003847","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"2025-02-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}